Metastatic lymph node characteristics as predictors of recurrence/persistence in the neck and distant metastases in differentiated thyroid cancer

Barbosa, Mayara Peres; Momesso, Denise; Bulzico, Daniel; Farias, Terence Pires de; Dias, Fernando Luiz; Lima, Roberto A.; Corbo, Rossana; Vaisman, Fernanda

doi:10.1590/2359-3997000000307

Cited by 18 publications

(24 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Papillary thyroid cancer and follicular thyroid cancer are the major subtype of thyroid cancer, and frequently have a favorable prognosis. 5 Thus, it is necessary to identify reliable biomarkers for predicting clinical progression and prognosis, which may be useful to improve the survival of thyroid cancer patients. 5 Thus, it is necessary to identify reliable biomarkers for predicting clinical progression and prognosis, which may be useful to improve the survival of thyroid cancer patients.…”

Section: Introductionmentioning

confidence: 99%

SNHG15 functions as a tumor suppressor in thyroid cancer

Liu

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Small nucleolar RNA host gene 15 (SNHG15) has been suggested to be overexpressed, and function as an oncogenic long noncoding RNA (lncRNA) in various types of human malignancies. However, the expression status and function of SNHG15 were still unknown in thyroid cancer. In our study, we assessed the expression status and clinical value in thyroid cancer samples, and explored the effect of SNHG15 on thyroid cancer cell proliferation, migration, and invasion. In results, SNHG15 expression was downregulated in thyroid cancer tissues and cells, and correlated with age, pathology classification, clinical stage, tumor size, distant metastasis, and disease‐free survival. The in vitro studies suggested SNHG15 overexpression suppressed cell proliferation, migration, and invasion in thyroid cancer. In summary, SNHG15 serves as tumor suppressive role in thyroid cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

SNHG15 functions as a tumor suppressor in thyroid cancer

Liu

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…In addition, the survival rates of patients with PTC and FTC have been reported to be significantly associated with DM (14,15). Lymph node metastasis (LNM) status and tumor size are also associated with DM in patients with PTC (16,17). Previous studies have also identified ETE and LNM status as independent risk factors for DM in patients with DTC (18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Innovative analysis of distant metastasis in differentiated thyroid cancer

et al. 2020

View full text Add to dashboard Cite

Differentiated thyroid cancer (DTC) is the most common thyroid cancer with a relatively high survival rate. The association between certain risk factors of distant metastasis (DM) remains uncertain. In order to assess the prognosis of patients with DTC better, the present study aimed to investigate the synergistic effects between histologic subtype, tumor size, lymph node metastasis (LNM) status and extrathyroidal extension (ETE) on the incidence of DM in DTC. Data of 96,788 patients with DTC were obtained from the Surveillance, Epidemiology and End Results database. The association between clinicopathological factors and DM was evaluated by univariate and multivariate analyses. The synergistic effects of relevant factors were determined by measuring the relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP) and synergy index (SI). The results demonstrated that tumor size, LNM status, histologic subtype and ETE were independent risk factors for DM [odds ratio (OR)=2.433; P<0.001; OR=3.998; P<0.001; OR=6.266; P<0.001; and OR=3.873; P<0.001, respectively]. In addition, a significant additive synergistic effect on DM was identified between ETE and histologic subtype, ETE and LNM status, as well as between ETE and tumor size (RERI=34.097; AP=0.706; SI=3.585; RERI=6.425; AP=0.410; SI=1.781; and RERI=76.973; AP=0.864; SI=7.930, respectively). Therefore, the results of this study revealed that ETE with follicular thyroid histology, N1 stage or large tumor size may have a synergistic effect on the risk of DM in patients with DTC. These results suggested that individualized treatment may benefit patients with DTC, and when ETE coexists with one of the identified risk factors, radical treatments may be required.

show abstract

“…Identifying patients at risk of DM is therefore a critical step in the management of DTC so that appropriate treatments can be initiated. A number of prognostic factors including age, gender, histology, tumour size, vascular invasion (VI), lymph node metastasis (LNM) and extra‐thyroidal extension (ETE) have been identified as predictors of DM in DTC 5–8,11–21 . However, there is ongoing debate as conflicting results have been illustrated by other investigators.…”

Section: Introductionmentioning

confidence: 99%

Predicting distant metastatic disease in differentiated thyroid cancer: a matchedcase–controlstudy

Jaffar

Jayasekara

Aniss

et al. 2021

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background The occurrence of distant metastasis (DM) is the most important prognostic factor influencing survival outcomes in differentiated thyroid cancer (DTC). Identifying patients who are likely to develop DM and offering these cases more aggressive surgical approaches and I‐131 therapy, is paramount to achieving the best possible outcomes. DM on presentation in DTC are uncommon, with an incidence of 1–9%. However, the incidence of DTC is rising and the disease affects a relatively young cohort of patients. The aims of this study were to investigate predictive factors in the development of DM by comparing a homogenous group of DTC patients with and without DM, and to illustrate the overall and disease‐specific survival (DSS) rates of DTC patients presenting with DM. Methods A matched case–control study of patients with DTC and DM was undertaken. The study group comprised a consecutive series of cases with DM treated in the period 1968–2014. Patients with DM at initial presentation were identified (DTC‐DM group). A control group of patients without DM were matched based on age, gender, tumour size and histological subtype. The primary outcome measures were overall and disease‐free survival. Secondary outcome measures were lymph node involvement (LNI), extra‐thyroidal extension (ETE) of tumour and presence of BRAFV600E mutation identified on immunohistochemistry. Results A total of 2547 patients with DTC were reviewed and of these 83 (3.26%) had DM at initial presentation. At 5 and 10 years, the overall survival rates for DTC‐DM patients were 89.6% and 64%, respectively. The 5 and 10 year DSS rates for DTC‐DM cases were 90.2% and 67.3%, respectively. When compared to the DTC group, the DTC‐DM group had significantly higher rates of ETE (63% vs. 29.5%, P < 0.0001) and LNI (32.5% vs. 18.8%, P = 0.044). Among patients with papillary thyroid cancer (PTC), the presence of BRAFV600E mutation was significantly associated with DM (62.2% vs. 36.8%, P = 0.028). Conclusion ETE, LNI and BRAFV600E mutation in PTC are significant predictors for the development of distant metastatic disease.

show abstract

Metastatic lymph node characteristics as predictors of recurrence/persistence in the neck and distant metastases in differentiated thyroid cancer

Cited by 18 publications

References 22 publications

SNHG15 functions as a tumor suppressor in thyroid cancer

SNHG15 functions as a tumor suppressor in thyroid cancer

Innovative analysis of distant metastasis in differentiated thyroid cancer

Predicting distant metastatic disease in differentiated thyroid cancer: a matchedcase–controlstudy

Contact Info

Product

Resources

About